$18.35
0.71%
Downside
Day's Volatility :5.3%
Upside
4.63%
48.56%
Downside
52 Weeks Volatility :73.96%
Upside
49.38%
Period | 4d Molecular Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -20.34% | 6.5% | 0.0% |
6 Months | 5.83% | 7.1% | 0.0% |
1 Year | 3.0% | 9.8% | 0.0% |
3 Years | -23.34% | 14.2% | -20.2% |
Market Capitalization | 969.4M |
Book Value | $11.74 |
Earnings Per Share (EPS) | -2.36 |
Wall Street Target Price | 50.6 |
Profit Margin | 0.0% |
Operating Margin TTM | -136200.0% |
Return On Assets TTM | -17.29% |
Return On Equity TTM | -25.53% |
Revenue TTM | 20.5M |
Revenue Per Share TTM | 0.47 |
Quarterly Revenue Growth YOY | -90.60000000000001% |
Gross Profit TTM | -77.1M |
EBITDA | -116.5M |
Diluted Eps TTM | -2.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.94 |
EPS Estimate Next Year | -3.36 |
EPS Estimate Current Quarter | -0.74 |
EPS Estimate Next Quarter | -0.73 |
What analysts predicted
Upside of 175.75%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 14.1M | ↑ 144.04% |
Net Income | -9.6M | ↓ 14.9% |
Net Profit Margin | -67.59% | ↑ 126.24% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 7.0M | ↓ 50.56% |
Net Income | -52.9M | ↑ 454.28% |
Net Profit Margin | -757.79% | ↓ 690.2% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 13.6M | ↑ 94.85% |
Net Income | -56.5M | ↑ 6.8% |
Net Profit Margin | -415.38% | ↑ 342.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 18.0M | ↑ 32.52% |
Net Income | -68.3M | ↑ 20.79% |
Net Profit Margin | -378.63% | ↑ 36.75% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.1M | ↓ 82.65% |
Net Income | -101.1M | ↑ 47.99% |
Net Profit Margin | -3.2K% | ↓ 2851.67% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.7M | ↑ 562.29% |
Net Income | -100.8M | ↓ 0.24% |
Net Profit Margin | -486.59% | ↑ 2743.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.2M | ↑ 149.4% |
Net Income | -27.3M | ↑ 13.2% |
Net Profit Margin | -2.2K% | ↑ 2631.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 298.0K | ↓ 76.1% |
Net Income | -27.3M | ↓ 0.05% |
Net Profit Margin | -9.1K% | ↓ 6959.89% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 239.0K | ↓ 19.8% |
Net Income | -29.6M | ↑ 8.65% |
Net Profit Margin | -12.4K% | ↓ 3244.65% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.2M | ↑ 8353.56% |
Net Income | -10.3M | ↓ 65.37% |
Net Profit Margin | -50.76% | ↑ 12340.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | -19.0K | ↓ 100.09% |
Net Income | -32.3M | ↑ 214.77% |
Net Profit Margin | 169.9K% | ↑ 169961.29% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 28.0K | ↓ 247.37% |
Net Income | -32.4M | ↑ 0.37% |
Net Profit Margin | -115.7K% | ↓ 285628.39% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 97.0M | ↑ 254.94% |
Total Liabilities | 124.6M | ↑ 165.52% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 58.2M | ↓ 39.95% |
Total Liabilities | 131.2M | ↑ 5.34% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 288.3M | ↑ 395.12% |
Total Liabilities | 31.9M | ↓ 75.65% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 353.5M | ↑ 22.6% |
Total Liabilities | 560.5M | ↑ 1654.58% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 261.8M | ↓ 25.92% |
Total Liabilities | 30.5M | ↓ 94.56% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 339.9M | ↑ 29.81% |
Total Liabilities | 32.1M | ↑ 5.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 261.8M | ↓ 6.54% |
Total Liabilities | 30.5M | ↑ 6.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 244.0M | ↓ 6.81% |
Total Liabilities | 25.4M | ↓ 16.7% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 352.5M | ↑ 44.46% |
Total Liabilities | 725.3M | ↑ 2753.79% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 361.6M | ↑ 2.58% |
Total Liabilities | 31.7M | ↓ 95.63% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 339.9M | ↓ 6.01% |
Total Liabilities | 32.1M | ↑ 1.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 629.9M | ↑ 85.32% |
Total Liabilities | 29.3M | ↓ 8.54% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.3M | ↓ 297.3% |
Investing Cash Flow | -414.0K | ↓ 105.39% |
Financing Cash Flow | 84.6M | ↑ 528506.25% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -36.7M | ↑ 125.89% |
Investing Cash Flow | -3.2M | ↑ 673.67% |
Financing Cash Flow | -2.2M | ↓ 102.6% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -50.9M | ↑ 38.68% |
Investing Cash Flow | -1000.0K | ↓ 68.78% |
Financing Cash Flow | 279.0M | ↓ 12809.93% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -69.1M | ↑ 35.8% |
Investing Cash Flow | -172.7M | ↑ 17168.0% |
Financing Cash Flow | 118.1M | ↓ 57.67% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -86.7M | ↑ 25.39% |
Investing Cash Flow | -17.1M | ↓ 90.13% |
Financing Cash Flow | 3.1M | ↓ 97.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.2M | ↑ 5.7% |
Investing Cash Flow | -35.8M | ↓ 332.77% |
Financing Cash Flow | 2.0M | ↑ 344.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -27.9M | ↑ 25.62% |
Investing Cash Flow | 43.1M | ↓ 220.55% |
Financing Cash Flow | 11.0M | ↑ 437.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.1M | ↓ 20.93% |
Investing Cash Flow | 49.3M | ↑ 14.28% |
Financing Cash Flow | 130.5M | ↑ 1087.18% |
Sell
Neutral
Buy
4d Molecular Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() 4d Molecular Therapeutics Inc | -11.85% | 5.83% | 3.0% | -23.34% | -54.27% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() 4d Molecular Therapeutics Inc | NA | NA | NA | -2.94 | -0.26 | -0.17 | NA | 11.74 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() 4d Molecular Therapeutics Inc | Buy | $969.4M | -54.27% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on 4d Molecular Therapeutics Inc
Revenue is up for the last 2 quarters, -19.0K → 28.0K (in $), with an average increase of 167.9% per quarter
Netprofit is down for the last 3 quarters, -10.25M → -32.40M (in $), with an average decrease of 107.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 58.6%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 209.8%
RA Capital Management, LLC
VR Adviser, LLC
BlackRock Inc
Bvf Inc
HHG PLC
Goldman Sachs Group Inc
the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim
Organization | 4d Molecular Therapeutics Inc |
Employees | 171 |
CEO | Dr. John F. Milligan Ph.D. |
Industry | Healthcare |